Innovation for Good Health
Fosun Pharma USA Inc. is led by a team of highly experienced executives with strong track records from leading US and European pharmaceutical companies both in commercial operations and R&D.
As Chief Executive Officer, Rong Yang leads Fosun Pharma USA in its business and purpose. Rong is also the Senior Vice President of Fosun Pharma Group, a leading innovation-driven international healthcare group listed in the Shanghai and Hong Kong Stock exchange. Since he took the reins as CEO in January 2022, Rong accelerated Fosun Pharma USA’s transformation into an innovation-driven healthcare company serving patients and customers in the US.
Prior to Fosun Pharma, Rong was with Bayer Group for nearly 20 years in a variety of senior positions across a range of markets including Vice President, Head of Specialty Sales with Bayer U.S.; Vice President of Business Insight US; Vice President of Finance and Strategy Americas; Country General Manager Czech Republic & Slovakia; Head of Marketing and Sales Specialty with Bayer Austria. Rong has lived and worked in five different countries across three continents.
Rong holds a Bachelor’s degree in Art from Beijing Foreign Studies University, a Master of Economics from Nankai University, and a Master of Business Administration from Harvard University.
Rong serves as Director on the Board of Nature Sunshine, a NASDAQ listed company.
Dr. Lijun Wu is the Chief Scientific Officer and Founder, Head of FUSION BioVenture. She founded FUSION, Fosun Pharma’s innovation incubation platform in the US, which incubated andlaunched Archimmune Therapeutics and Leverna Therapeutics, where she is the Chair of the Board. She is also the acting CEO of Leverna. Prior to joining Fosun Pharma in 2018, she was an Entrepreneur-in-Residence at Atlas Venture and Senior Vice President of Preclinical and Clinical Development at Delinia. Prior to that, Dr. Wu held various senior leadership positions including Concert Pharmaceuticals (VP), Resolvyx Pharmaceuticals (VP), Novartis Institutes for BioMedical Research (Executive Director), and Millennium Pharmaceuticals (Director).
Dr. Wu is a seasoned executive with >25-years of experience in R&D, investment, and BD in startups established biotech, and large pharmaceutical companies in the US and across borders. She is an author of ~70 peer-reviewed publications, an inventor on a number of patents, and the recipient of Massachusetts High Tech’s “Women to Watch” award. She has been serving on the advisory council of IBBS/Johns Hopkins School of Medicine and is a member of JHU’s Society of Scholars.
Dr. Wu received her Ph.D. in Biochemistry, Molecular Biology, and Cell Biology from Northwestern University and completed a postdoctoral fellowship at Johns Hopkins University School of Medicine.
Kitty Wu is Fosun Pharma USA’s VP and Head of Business Development and Strategy for Innovative Medicine.
She brings 25 years of research, venture capital, business development, and strategy experience to Fosun. Prior to Fosun Kitty worked at Roche/Genentech for 11 years where she held roles of increasing responsibility in portfolio and disease strategy, business development, and commercialization across multiple therapeutic areas. Her roles spanned global as well as the U.S. and China affiliates.
Kitty received her Ph.D. in neuroscience from the University of Rochester and earned an NRSA grant for her post-doctoral research in the lab of Dr. Jim Eberwine at the University of Pennsylvania. Kitty has published multiple first-author research and review papers and is also an inventor, holding two patents from her time at Penn.
As the SVP, Head of Commercial for our new Innovative Medicines Group, Mousumi Sannigrahi is responsible for building an industry-leading commercial footprint in the USA to serve patients and customers in the US.
Mousumi is a seasoned leader, passionate about bringing therapeutic innovations to the market. Prior to joining Fosun, Mousumi was the US Head of CSU, Immunology at Novartis. Additionally, she held different global and US leadership roles with increasing responsibilities in Strategy, Sales, and Marketing at Novartis and Sunovion. At LEK Consulting, as a Management Consultant, Mousumi was responsible for commercial, pipeline and investment strategies for Pharma, Biotech, and Private Equity Firms. She started her career at Schering Plough in R&D as a Medicinal Chemist in Infectious Diseases and Oncology.
Mousumi holds a Ph.D. degree in organic chemistry from the University of Alberta and an MBA degree from Duke University.
Jeremy is responsible for Commercial Operations, BD and Investment activities in the US.
Jeremy brings 25+ years of industry experience in Commercial Operation and Strategy in both brand and generic pharmaceuticals to Fosun Pharma USA. He has previously held positions of ever increasing responsibility at Merck, Cubist, EKR Therapeutics, AuroMedics, American Regent and Slayback Pharma where he was Vice President of Sales before joining Fosun Pharma USA.
Chris is responsible for BD&L activities in the US and has 25 years of pharmaceutical industry experience spanning business and scientific disciplines.
Chris’ prior scientific experience includes positions of increasing responsibility at Organogenesis, Genetics Institute/Wyeth, and Novartis (NIBR). His business and corporate development experience includes positions of increasing responsibility at Indevus Pharmaceuticals, Endo International, and Teva Pharmaceuticals and encompasses a wide range of transactions including: in- and out-licensing, asset acquisitions and divestitures, and M&A in both the generics and branded pharmaceutical spaces.
Chris received his B.S. in Biology from the University of Massachusetts at Lowell, his A.L.M with a concentration in molecular biology and original thesis work in RNA interference from Harvard University, and his M.B.A. from Boston University.
Huong Nguyen is currently Vice President, General Counsel, of Fosun Pharma USA Inc. She has spent the majority of her nearly two-decade law practice actively working in the pharmaceutical industry as both an in-house counsel and a private practitioner. Throughout this time she has partnered with a wide variety of cross-functional groups, and has directly counseled senior management and Boards of Directors in her areas of expertise.
Huong spent the early years of her legal career in private practice at two consecutive national (US) law firms as a commercial and IP litigator and IP counsel. Thereafter, she spent almost ten years at a specialty pharmaceutical company as in-house counsel, with increasing responsibilities through the years in litigation, IP, and employment matters. While in-house, Huong also spearheaded internal and government investigations that resulted in her appearing before the US Federal Trade Commission, US Department of Justice, and State Attorneys General in defense of the company. She left her first pharmaceutical company for private practice in order to expand her experience in M&A and BD and commercial transactions.
In 2019, Huong joined Fosun as General Counsel, with deep and wide-ranging experiences in litigation, IP, compliance, M&A, BD and commercial transactions, and employment. During the COVID-19 pandemic, Huong also assisted Fosun in the sales and distribution of medical supplies and devices, including PPE and Fosun’s own RT-PCR and Antibody Detection Kits.
Huong received her BA at the University of California, Los Angeles and her JD at the University of California, Hastings College of the Law.